



**This document was valid from 13 July 2006 until February 2016. It is now superseded by a [new version](#) adopted by the HMPC on 2 February 2016 and published on the EMA website.**

**LIST OF REFERENCES SUPPORTING THE ASSESSMENT REPORT ON:**

*Valeriana officinalis* L., radix  
(EMEA/HMPC/167391/2006)

*The EMEA acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.*

1. Ad hoc working group on herbal medicinal products of the EMEA Final Proposal for a core-data for *Valerianae radix* (EMEA/HMPWG/14/99) September 1998
2. Albrecht M, Berger W, Laux P, Schmidt U, et al.: Psychopharmaka und Verkehrssicherheit. Der Einfluß von Euvegal® - Dragees forte auf die Fahrtüchtigkeit und Kombinationswirkungen mit Alkohol. Z. Allg. Med. 1995; 71: 1215-25
3. Angst J, Borebely A, Engel RR, et al.: Report on the sixth consensus conference on the methodology of clinical trials with hypnotic drugs. Pharmacopsychiat 1995; 28: 2-7
4. Balderer G, Borbely AA: Effect of valerian on human sleep. Psychopharmacol 1985; 87: 406-9
5. Balduini W, Cattabeni F: Displacement of [<sup>3</sup>H] N<sup>6</sup>-cyclohexyladenosine binding to rat cortical membranes by an hydroalcoholic extract of *Valeriana officinalis*. Med. Sci Res. 1989; 17: 639-40
6. Bodesheim U, Hölzl J: Isolierung, Strukturaufklärung und Radiorezeptorassay von Alkaloiden und Lignanen aus *Valeriana officinalis* L. Pharmazie 1997; 52: 386-91
7. Bos R, Woerdenbag HJ, De Smet PAGM, et al.: Valeriana Species. In: DeSmet PGMA, Keller K, Haensel R, Chandler RD (eds): Adverse Effects of Herbal Drugs. Vol 3, Springer-Verlag Berlin, 1998; 165-80
8. Cavadas C, Araújo I, Cotrim MD, Amaral T, Cunha AP, Macedo T, Fontes Ribeiro C: *In vitro* Study on the Interaction of *Valeriana officinalis* L. Extracts and Their Amino Acids on GABA-A Receptor in Rat Brain. *Arzneim.-Forsch./Drug Res.* 1995; 45(II) No 7: 753-5
9. Coxeter PD, Schluter PJ, Eastwood HL, et al.: Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-1 trials. *Complementary Therapies in Medicine* 2003; 11: 215-22
10. Cropley M, Cave Z, Ellis J, Middleton RW: Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. *Phytotherapy Research* 2002; 16: 23-7
11. Diaper A, Hindmarch I: A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults. *Phytotherapy Res* 2004; 18: 831-6
12. Donath F; Quispe S; Diefenbach K; et al.: Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. *Pharmacopsych* 2000; 33: 47-53

13. Donovan JL, DeVane CL, Chavin KD, et al.: Multiple night time doses of valerian (*Valeriana officinalis*) had minimal effects on CYP 3A4 activity and no effect on CYP 2D6 activity in healthy volunteers. *Drug Metab Dispos* 2004
14. Dorn M: Efficacy and tolerability of valerian versus oxazepam in non-organic and non-psychiatric insomnias: a randomized, double-blind, clinical, comparative study. *Komplementaermedizin und Klassische Naturheilkunde* 2000; 7: 79-84
15. ESCOP Monograph: *Valerianae radix*. European Scientific Cooperative on Phytomedicine, July 1997
16. Fehri B, Aiache JM, Boukef K, Memmi A, Hizaoui B: *Valeriana officinalis* et *Crataegus oxyacantha*: Toxicité par administrations réitérées et investigations pharmacologiques. *J. Pharm. Belg.* 1991; 46/3: 165-76
17. Feldmeier Ch, Kapp W: Comparative clinical studies with midazolam, oxazepam and placebo. *Br J Clin Pharmacol* 1983; 16, 151S-155S
18. Fernández S, Wasowski C, Paladini AC, marder M: Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from *Valeriana officinalis*. *Pharm Biochem Behav* 2004; 77: 399-404
19. Ferreira F, Santos MS, Faro C, et al.: Effect of extracts of *Valeriana officinalis* on [<sup>3</sup>H]GABA. *Rev Port Farm* 1996; 46: 74-7
20. Garges HP, Varia I, Doraiswamy PM: Cardiac complications and delirium associated with valerian root withdrawal. *JAMA* 1998; 280: 1566-7
21. Gerhard U, Linnenbrink N, Georghiadou C, Hobi V: Vigilanzmindernde Effekte zweier pflanzlicher Schlafmittel. *Schweiz. Rundsch. Med. (Praxis)* 85 1996; 15: 473-81
22. Goldstein SE, et al.: Comparison of oxazepam, flurazepam and chloral hydrate as hypnotic sedatives in geriatric patients. *J Am Geriatr Soc* 1978, 26: 366-71
23. Gurley BJ, Gardner SF, Hubbard MA, et al.: In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1a<sup>α</sup>; „D6, 2E1, and 3A4/5 phenotypes. *Clin Pharmacol Therapeutics* 2005; 415-26
24. Gutierrez S, Ang-Lee MK, Walker D, Zacny JP: Assessing subjective and psychomotor effects of the herbal medication valerian in healthy volunteers. *Pharmacol Biochem Behav* 2004; 78: 57-64
25. Hallam KT, Olver JS, McGrath C, Norman TR: Comparative cognitive and psychomotor effects of single doses of *Valeriana officinalis* and triazolam in healthy volunteers. *Human Psychopharmacology* 2003; 18: 619-25
26. Hänsel R, Keller K, Rimpler H, Schneider G (eds): *Hagers Handbuch der Pharmazeutischen Praxis*. Monograph: *Valeriana*. Vol. 6: Drogen P-Z, 5<sup>th</sup> ed. Springer publishers, Berlin Heidelberg New York. 1994: 1067-95
27. Hänsel R, Sticher O, Steinegger G (eds.). *Pharmakognosie - Phytopharmazie*, Springer Verlag Berlin Heidelberg New York 1999
28. Hazelhoff B, Malingré TH M, Meijer DKF: Antispasmodic Effects of *Valeriana* Compounds. An in-Vivo and in-Vitro Study on the Guinea-Pig Ileum. *Arch. Int. Pharmacodyn.* 1982; 257: 274-87
29. Hendriks H, Bos R, Allersma DP, Malingré Th M, Koster AS: Pharmacological screening of valeranal and some other components of essential oil of *Valeriana officinalis*. *Planta Medica* 1981; 42: 62-8
30. Hendriks H, Bos R, Woerdenbag HJ, Koster AS: Central nervous depressant activity of valerenic acid in the mouse. *Planta Med.* 1985; 51: 28-31

31. Herberg KW: Doppelblinde Crossoverstudie zum Einfluß einer Hopfen-Baldrian-Kombination (Ivel<sup>®</sup>) und von Placebo allein und in Kombination mit Alkohol auf Verkehrssicherheit und allgemeine Leistungsfähigkeit von Probanden (Study No. MI 9218). TÜV Rheinland, Köln, April 1994 (a)
32. Herberg KW: Psychotrope Phytopharmaka im Test: Alternative zu synthetischen Psychopharmaka? Therapiewoche 1994; 44 (12): 704-13
33. Hiller K-O, Kato G: Anxiolytic Activity of Psychotropic Plant Extracts. I. Test of Ethanolic *Valeriana* Extract STEI Val. 44<sup>th</sup> Annual Congress of the Society for Medical Plant Research, Prague 1996, Poster P 65
34. Hiller K-O, Zetler G: Neuropharmacological Studies on Ethanol Extracts of *Valeriana officinalis* L.: Behavioral and Anticonvulsant Properties. Phytotherapy Research. 1996; 10: 145-51
35. Hintelmann C: Sleep disorders in children: observational study with a high dosage valerian extract. Schweiz Z Ganzheits medizin 2002; 14: 404-7
36. Holm E, Kowollik H, Reinecke A, Henning v. GE, Behne F, Scherer H-D: Vergleichende neurophysiologische Untersuchungen mit Valtratum/Isovaltratum und Extractum Valerianae an Katzen. Med. Welt. 1980; 31 (26): 982-90
37. Houghton PJ: The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 1999 May; 51(5): 505-12
38. Jacobs BP, Bent S, Tice JA, et al.: An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine 2005; 84: 197-207
39. Kammerer E, Brattström A, Herberg KW: Einfluß einer Hopfen-Baldrian-Kombination auf Leistungsfähigkeit und Verkehrssicherheit. Der Bayerische Internist 1996; 16: 32-6
40. Kamm-Kohl AV, Jansen W, Brockmann P: Moderne Baldriantherapie gegen nervöse Störungen im Senium. Med. Welt 1984; 35: 1450-4
41. Kohnen R, Oswald W-D: The effects of valerian, propranolol, and their combination on activation, performance and mood on healthy volunteers under social stress conditions. Pharmacopsychiat. 1988; 21: 447-8
42. Kuhlmann J, Berger W, Prodzoweit H, et al.: The influence of valerian treatment on „reaction time, alertness and concentration“ in volunteers. Pharmacopsychiat 1999; 32: 235-41
43. Leathwood PD, Chauffard F, Heck E, Munoz-Box R: Aqueous extract of valerian Root (*Valeriana officinalis* L.) improves sleep quality in man. Pharmacol. Biochem. Behav. 1982; 17: 65-71
44. Leathwood PD, Chauffard F: Aqueous extract of valerian reduces latency to fall asleep in man Planta Medica 1985; 51: 144-8
45. Leathwood PD, Chauffard F: Quantifying the effects of mild sedatives. J. Psychiatr. Res. 1982/83; 17 (2): 115-22
46. Lefebvre T, Foster BC: In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharmaceut Sci 2004; 7: 265-73
47. Leuschner J, Müller J, Rudmann M: Characterisation of the central nervous depressant activity of a commercially available valerian root extract. Arzneimittel.-Forsch./Drug Res. 1993; 43(1) Nr. 6: 638-41
48. Marder M, Viola H, Wasowski C, et al.: 5-Methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS. Pharm Biochem Behav 2003; 75: 537-45
49. Mennini T, Bernasconi P, Bombardelli E, Morazzoni P: *In vitro* study on the interactions of extracts and pure compounds from *Valeriana officinalis* roots with GABA, benzodiazepine and barbiturate receptors in rat brain. Fitoterapia. 1993; 64/4: 291-300

50. Mueller CE, Schumacher B, Brattstroem A, et al.: Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors. *Life Sciences* 2002; 71: 1939-49
51. Ortiz JG; Nieves-Natal J; Chavez P: Effects of *Valeriana officinalis* extracts on [3H]flunitrazepam binding, Synaptosomal [3H]GABA Uptake, and Hippocampal [3H]GABA Release. *Neurochem Res* 1999; 24: 1373-8
52. Riedel E, Hänsel R, Ehrke G: Inhibition of  $\gamma$ -Aminobutyric Acid by Valerenic Acid Derivatives. *Planta Med.* 1982; 46: 219-20
53. Rosecrans JA, Defeo JJ, Youngken HW Jr: Pharmacological investigation of certain *Valeriana officinalis* L. extracts. *J Pharm Sci.* 1961; 50: 240-4
54. Rücker G, Tautges J, Sieck A, Wenzl H, Graf E: Untersuchungen zur Isolierung und pharmakodynamischen Aktivität des Sesquiterpens Valeranon aus *Nardostachys jatamansi* DC. *Arzneim.-Forsch./Drug Res.* 1978; 28 (I) No. 1: 7-13
55. Santos a Maria S et al: An aqueous extract of valerian influences the transport of GABA in synaptosomes. *Planta Med.* 1994; 60: 278-9
56. Santos b Maria S et al: The amount of GABA present in aqueous extracts of valerian is sufficient to account for [<sup>3</sup>H]-GABA release in synaptosomes. *Planta Med.* 1994; 60: 475-476
57. Santos c MS, Ferreira F, Cunha AP, Carvalho AP, Ribeiro CF, Macedo T: Synaptosomal GABA release as influenced by valerian root extract-involvement of the GABA carrier. *Arch Int Pharmacodyn Ther* 1994 Mar-Apr; 327(2): 220-31
58. Schulz H, Jobert M: Die Darstellung sedierender/tranquilisierender Wirkungen von Phytopharmaka im quantifizierten EEG. *Z. Phytotherapie*, 6. Phytotherapiekongreß, Berlin 1995; Abstractband: 10
59. Schulz H, Stolz C, Mueller J: The effect of valerian extract on sleep polygraphy in poor sleepers: A pilot study. *Pharmacopsychiat.* 1994; 27: 147-51
60. Schulz H; Jobert M; Huebner WD: The quantitative EEG as a screening instrument to identify sedative effects of single doses of plant extracts in comparison with diazepam. *Phytomedicine* 1998; 5: 449-58
61. Schumacher B, Scholle S, Hoelzl J, et al.: Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A<sub>1</sub> receptors. *J Nat Prod* 2002; 65: 1479-85
62. Torrent MT, Iglesias J, Adzet T: Valoración experimental de la actividad sedante de la tintura de *Valeriana officinalis* L. *Circular Farmacéutica.* 1972; 30: 107-12
63. von der Hude W; Scheutwinkel-Reich M; Braun R: Bacterial mutagenicity of the tranquilizing constituents of Valerianaceae roots. *Mutat.Res.* 1986; 169: 23-7
64. Von Skramlik E: Über die Giftigkeit und Verträglichkeit von ätherischen Ölen. *Pharmazie* 1959; 14: 435-45
65. Vorbach EU, Goertelmeyer R, Brüning J: Therapie von Insomnien. Wirksamkeit und Verträglichkeit eines Baldrianpräparates. *Psychopharmakotherapie* 1996; 3: 109-15
66. Wagner H, Jurcic K: *In vitro*- and *in vivo*-Metabolism of <sup>14</sup>C-Didrovaltrate. *Planta Med.* 1980; 38: 366-76
67. Wasowski C, Marder M, Viola H, et al.: Isolation and identification of 6-methylapigenin, a competitive ligand for the brain GABA<sub>A</sub> receptors, from *Valeriana wallichii*. *Planta Med.* 2002; 68: 934-6
68. WHO monographs on selected medicinal plants: *Radix Valeriana*. Volume 1 World Health Organization, Geneva 1999
69. Wiener SW, Hoffmann RS, Nelson LS: Withdrawal symptoms after valerian cessation. *Clin Tox* 2003; 41: 721

70. Willey LB, Mady SP, Cobaugh DJ, et al.: Valerian overdose: a case report. *Vet Human Toxicol* 1995; 37: 364-5
71. Yuan CH, Mehendale S, Yiao Y, et al.: The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. *Anesth Analg* 2004; 98: 353-8
72. Ziegler G, Ploch, Miettinen-Baumann A, Collet W: Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia – a randomized, double-blind, comparative clinical study. *Eur J Med Res* 2002; 7: 480-6
73. Benedum J, Loew D, Schilcher H: *Arzneipflanzen in der traditionellen Medizin. Kooperation Phytopharmaka.*
74. Berendes J: *Des Pedanios Dioskurides aus Anazarbos Arzneimittellehre in fuenf Buechern, Stuttgart 1902*
75. *British Herbal Pharmacopoeia, 1976*
76. Chamisso, A. von: *Illustriertes Heil-,Gift- und Nutzpflanzenbuch.* Ed. Schneebeil-Graf R, Berlin 1987
77. *Culbreth DMR: A manual of materia medica and pharmacology comprising the organic drugs which are or have been recognized by the United States Pharmacopoeia and national formulary. Philadelphia 1927.* Ed. Michael Moore, Southwest School of Botanical Medicine.
78. *Deutsches Arzneibuch 6. Ausgabe 1926, Berlin 1926*
79. Dragendorff G: *Die Heilpflanzen der verschiedenen Voelker und Zeiten.* Stuttgart 1898
80. Haffner Schultz Schmid Braun: *Normdosen gebraeuchlicher Arzneistoffe und Drogen.* 8. Auflage ed. R Braun, Stuttgart 1991
81. Hager H: *Commentar zur Pharmacopoeia Germanica.* , Baende, Berlin 1874/74
82. *Hagers Handbuch der Pharmazeutischen Praxis.* Eds List PH, Hoerhammer L, Berlin 1979
83. Madaus G: *Lehrbuch der biologischen Heilmittel.* 1938, Georg Thieme Verlag Leipzig
84. French Competent Authority: *Notice to manufacturers concerning marketing authorization applications for plant-based medicinal products.* 1990 (non official translation)
85. Usmanghani Kh, et al.: *Indusynic medicine. Traditional medicine of herbal, animal and mineral origin in Pakistan.* Karachi, 1997
86. Martindale W: *Extra Pharmacopoeia, 25<sup>th</sup> edition, 1967*
87. Sayre LE: *A manual of organic materia medica and pharmacognosy.* 4th edition, Philadelphia 1917
88. Viétz FB: *Icones plantarum medico-oeconomico-technologicarum, Vol I/II.* Wien 1800
89. Ward H: *Herbal manual.* London 1936
90. Weiss RF: *Lehrbuch der Phytotherapie.* Stuttgart, 1944
91. Hölzl J: *Baldrianwurzel.* *Z. Phytotherapie* 1998; 19: 47-54
92. Müller SF, Klement S. *A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children.* *Phytomedicine* 2006; DOI:10.1016/j.phymed.2006.01.013 (article in press)
93. Glass JR et al. *Acute pharmacological effects of temazepam, diphenhydramine and valerian in healthy elderly subjects* *J Clin Psychopharmacol* 2003; 23:260-8 #
94. Romero-Jiménez M. et al. *Genotoxicity and anti-genotoxicity of some traditional herbs.* *Mutat. Res.* 2005; 585: 147-55
95. Stevinson C, Ernst E. *Valerian for insomnia: a systematic review of randomized clinical trials.* *Sleep Med.* 2000; 1(2): 91-9

96. Al-Majed AA, Al-Yahya AA, Al-Bekairi AM et al. Studies on the cytological and biochemical effects of valerian in somatic and germ cells of Swiss albino mice. Food and Chemical Toxicology 2006; 44: 1830-7

Superseded